Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRUKINSA vs CALQUENCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue at position 481 in the BTK active site, leading to sustained inhibition of BTK activity. This blocks B-cell receptor (BCR) signaling, thereby inhibiting the proliferation, migration, and survival of malignant B cells.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.
Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy,Waldenström's macroglobulinemia (WM) in adult patients,Relapsed or refractory marginal zone lymphoma (MZL) in adult patients who have received at least one prior anti-CD20-based regimen,Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients
FDA-approved: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,FDA-approved: Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),Off-label: Treatment of Waldenström macroglobulinemia,Off-label: Treatment of marginal zone lymphoma
320 mg orally once daily or 160 mg orally twice daily.
100 mg orally twice daily.
4 hours (terminal), supports twice-daily dosing
Terminal elimination half-life is 8 hours at steady state, supporting twice-daily dosing.
Zanubrutinib is primarily metabolized by cytochrome P450 3A4 (CYP3A4). Following oral administration, it undergoes oxidation and further phase II metabolism. The major circulating metabolite is a product of CYP3A4-mediated oxidation.
Primarily metabolized by CYP3A4 to form acalabrutinib M27 (active metabolite). Minor routes include glutathione conjugation and hydrolysis. Acalabrutinib is also a substrate of CYP3A5 and to a lesser extent CYP2C8.
Biliary/fecal (87% as unchanged drug), renal (8% as unchanged drug)
Fecal (77%), renal (15% as unchanged drug and metabolites).
96% bound to plasma proteins (mainly albumin)
97% bound to plasma proteins (albumin and alpha-1 acid glycoprotein).
3.23 L/kg (central Vd), indicating extensive tissue distribution
Approximately 10 L/kg, indicating extensive tissue distribution.
Oral: 48% under fasting conditions; high-fat meal decreases AUC by 30%
Oral bioavailability is approximately 70%; absorption is unaffected by food.
No dose adjustment required for Cr Cl ≥30 m L/min. For Cr Cl <30 m L/min, reduce dose to 80 mg twice daily.
No dose adjustment required for Cr Cl >=30 m L/min. For Cr Cl <30 m L/min, reduce dose to 100 mg once daily.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 80 mg twice daily. Child-Pugh C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 100 mg once daily. Child-Pugh C: avoid use.
Safety and efficacy not established; no approved dosing.
Not established for pediatric patients.
No specific dose adjustment; monitor for increased toxicity due to age-related renal/hepatic decline.
No specific dose adjustment beyond standard monitoring for toxicity.
None
None
Hemorrhage: Serious and fatal hemorrhagic events may occur. Monitor for signs of bleeding. Consider benefit-risk in patients requiring antiplatelet or anticoagulant therapy.,Infections: Fatal and serious infections (including pneumonia, sepsis) have occurred. Monitor for signs of infection and manage promptly.,Cytopenias: Neutropenia, thrombocytopenia, and anemia may occur. Monitor blood counts regularly.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor for symptoms of arrhythmia and manage appropriately.,Second primary malignancies: Including non-melanoma skin cancer, have been reported. Advise patients to use sun protection.,Tumor lysis syndrome: Can occur. Assess risk and monitor patients appropriately.
Hemorrhage: Fatal and serious bleeding events have occurred. Monitor for signs of bleeding, especially in patients on antithrombotic agents or with thrombocytopenia. Consider benefit-risk of holding acalabrutinib for 3-7 days pre- and post-surgery.,Infections: Fatal and serious infections, including opportunistic infections, have occurred. Monitor for signs and symptoms of infection and treat promptly.,Cytopenias: Grade 3 or 4 cytopenias (neutropenia, anemia, thrombocytopenia) can occur. Monitor complete blood counts regularly.,Second primary malignancies: Including skin cancers and other solid tumors. Advise patients to use sun protection.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor for cardiac arrhythmias and manage appropriately.,Hepatotoxicity: Elevations in liver enzymes have occurred. Monitor liver function tests.,Interstitial lung disease (ILD): Cases of ILD/pneumonitis have occurred. Monitor for pulmonary symptoms and manage as indicated.
None
None (no absolute contraindications). Avoid use in patients with severe hepatic impairment (Child-Pugh class C) due to lack of data; use with caution in moderate impairment (Child-Pugh class B).
Avoid grapefruit products and Seville oranges. No significant food effect on absorption; may be taken with or without food.
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit (which contain strong CYP3A4 inhibitors) during treatment with CALQUENCE. No other specific food restrictions are required. The drug can be taken with or without food.
Based on animal studies and mechanism of action (BTK inhibitor), BRUKINSA (zanubrutinib) can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, administration of zanubrutinib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity including increased post-implantation loss, reduced fetal body weights, and increased incidence of skeletal variations at exposures less than or equal to human clinical exposure at the recommended dose of 320 mg daily. Therefore, avoid use during pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus. If used, advise pregnant women of the potential risk to the fetus.
Based on animal studies and its mechanism of action (Bruton's tyrosine kinase inhibitor), CALQUENCE (acalabrutinib) may cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of acalabrutinib to pregnant rats during organogenesis resulted in embryofetal mortality and malformations at exposures below the clinical exposure at the recommended human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester exposure poses highest risk; second and third trimesters also carry risk of fetal toxicity.
There are no data on the presence of zanubrutinib in human milk, effects on the breastfed child, or effects on milk production. Zanubrutinib and its metabolites are excreted in the milk of lactating rats with concentrations approximately 2 times higher than maternal plasma (M/P ratio approximately 2). Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with BRUKINSA and for at least 2 weeks after the last dose.
No data are available on the presence of acalabrutinib or its metabolites in human milk, effects on the breastfed child, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with CALQUENCE and for at least 2 weeks after the last dose. M/P ratio is unknown.
No specific dose adjustments are recommended for BRUKINSA during pregnancy due to lack of pharmacokinetic data in pregnant women. However, pregnancy-induced physiological changes (e.g., increased plasma volume, altered hepatic metabolism) may affect drug concentrations. Standard dosing (320 mg once daily or 160 mg twice daily) is used if treatment is deemed necessary, with close monitoring for efficacy and toxicity. There are no pregnancy-specific pharmacokinetic studies to guide dose modification.
No specific dose adjustments are recommended for pregnancy due to lack of data on pharmacokinetic changes. However, because of potential alterations in drug metabolism and clearance during pregnancy, therapeutic drug monitoring may be considered if available. The manufacturer does not provide guidance for dose adjustment in pregnant women; use during pregnancy should be avoided unless clearly needed.
Monitor for atrial fibrillation/flutter and hemorrhage; baseline ECG recommended. Dose adjust for severe hepatic impairment (Child-Pugh C). Avoid strong or moderate CYP3A inhibitors/inducers; use with caution in patients requiring antiplatelet or anticoagulant therapy.
CALQUENCE (acalabrutinib) is a selective BTK inhibitor used in B-cell malignancies. It has fewer off-target effects than ibrutinib, particularly less atrial fibrillation and bleeding. Monitor for atrial fibrillation, hypertension, infections (especially respiratory), and bleeding events. Drug interactions with CYP3A4 inducers/inhibitors are significant; avoid concurrent use with strong CYP3A4 inhibitors or inducers. May need to hold for 3 days before and after procedures due to bleeding risk. Consider antiviral prophylaxis for herpes zoster in high-risk patients. Do not crush or break capsules; swallow whole with water. Dose adjustment for severe hepatic impairment (Child-Pugh C) is required.
Take BRUKINSA with or without food, but avoid grapefruit and Seville oranges.,Swallow capsules whole; do not crush or chew.,Inform your doctor of any bleeding or bruising, irregular heartbeat, or signs of infection.,Do not use antacids, proton pump inhibitors, or histamine-2 blockers without consulting your doctor.,If you miss a dose, take it as soon as remembered unless it is less than 12 hours until the next dose; then skip the missed dose.
Take CALQUENCE exactly as prescribed, usually twice daily with or without food. Swallow capsules whole; do not open, break, or chew them.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while taking this medication, as they can affect how the drug works.,Tell your healthcare provider about all medications you take, including prescription, over-the-counter, vitamins, and herbal products, especially St. John's wort.,CALQUENCE can increase your risk of serious infections, bleeding problems, and heart rhythm issues. Report any signs of infection (fever, chills), unusual bruising or bleeding, palpitations, or dizziness.,Do not stop taking CALQUENCE without consulting your healthcare provider. If you miss a dose, take it as soon as you remember unless it is less than 6 hours until your next dose; then skip the missed dose.,Women who are pregnant or breastfeeding should not take CALQUENCE. Effective contraception is needed during treatment and for 1 week after the last dose.,Keep CALQUENCE in the original container at room temperature (68°F to 77°F), away from moisture and light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRUKINSA vs CALQUENCE, answered by our medical review team.
BRUKINSA is a Antineoplastic BTK Inhibitor that works by Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue at position 481 in the BTK active site, leading to sustained inhibition of BTK activity. This blocks B-cell receptor (BCR) signaling, thereby inhibiting the proliferation, migration, and survival of malignant B cells.. CALQUENCE is a BTK Inhibitor that works by Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRUKINSA and CALQUENCE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRUKINSA is: 320 mg orally once daily or 160 mg orally twice daily.. The standard adult dose of CALQUENCE is: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRUKINSA and CALQUENCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRUKINSA is classified as Category C. Based on animal studies and mechanism of action (BTK inhibitor), BRUKINSA (zanubrutinib) can cause fetal harm when administered to a pregnant woman. There are no adequate and well-. CALQUENCE is classified as Category C. Based on animal studies and its mechanism of action (Bruton's tyrosine kinase inhibitor), CALQUENCE (acalabrutinib) may cause fetal harm when administered to a pregnant woman. In a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.